Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BABA-W
09988
5
JD-SW
09618
| (Q3)Jul 31, 2025 | (Q2)Apr 30, 2025 | (Q1)Jan 31, 2025 | (FY)Oct 31, 2024 | (Q4)Oct 31, 2024 | (Q3)Jul 31, 2024 | (Q2)Apr 30, 2024 | (Q1)Jan 31, 2024 | (FY)Oct 31, 2023 | (Q4)Oct 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -283.10%-69.86K | 15.45%-67.48K | -40.80%-54.07K | -79.58%-177.1K | -302.21%-40.65K | 55.31%-18.24K | -226.71%-79.81K | 28.21%-38.4K | -206.99%-98.62K | -22.81%20.1K |
| Net income from continuing operations | -91.17%-46.23K | 34.35%-29.23K | -93.50%-21.58K | -1,820.83%-2.59M | -38,263.13%-2.51M | 37.97%-24.18K | -63.37%-44.51K | 81.99%-11.15K | -148.29%-134.7K | -403.58%-6.54K |
| Asset impairment expenditure | --0 | --0 | --0 | --2.45M | --2.45M | --0 | --0 | --0 | --0 | ---- |
| Other non cashItems | --0 | ---1 | --2 | ---- | ---- | --1 | ---- | ---- | ---- | ---- |
| Change In working capital | -497.28%-23.63K | -8.37%-38.25K | -19.23%-32.49K | -220.17%-43.36K | -50.29%13.24K | 427.35%5.95K | -1,352.66%-35.3K | -422.93%-27.25K | 63.06%36.08K | 11.50%26.64K |
| -Change in receivables | -0.90%5.09K | 22.31%-2.42K | -153.21%-1.38K | 130.54%649 | 60.33%-818 | 382.44%5.13K | -210.72%-3.12K | 48.78%-545 | -193.51%-2.13K | -48.45%-2.06K |
| -Change in prepaid assets | -3,619.12%-28.72K | -172.18%-15.83K | -857.84%-7.82K | -1,062.72%-61.47K | -21,756.42%-55.66K | --816 | ---5.82K | 85.28%-816 | -871.88%-5.29K | 131.50%257 |
| -Change in payables and accrued expense | --0 | 24.14%-20K | 10.03%-23.29K | -59.83%17.47K | 145.09%69.72K | --0 | ---26.36K | -272.05%-25.89K | 85.91%43.49K | 8.99%28.45K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -283.10%-69.86K | 15.45%-67.48K | -40.80%-54.06K | -79.58%-177.1K | -302.22%-40.65K | 55.31%-18.24K | -226.73%-79.81K | 28.21%-38.4K | -206.99%-98.62K | -22.81%20.1K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | -7.19%-52.58K | -219.97%-35.17K | 45.71%-17.02K | -5.48%-385 | 0 | -5.13%-49.05K | 281.51%29.32K |
| Net PPE purchase and sale | --0 | --0 | --0 | -7.19%-52.58K | -219.97%-35.17K | 45.71%-17.02K | -5.48%-385 | --0 | -5.13%-49.05K | 281.51%29.32K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | -7.19%-52.58K | -219.97%-35.17K | 45.71%-17.02K | -5.48%-385 | --0 | -5.13%-49.05K | 281.51%29.32K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | ||||||||||
| Cash from discontinued financing activities | ||||||||||
| Net cash flow | ||||||||||
| Beginning cash position | -49.18%240.39K | -44.35%307.87K | -38.82%361.93K | -19.97%591.61K | -28.67%437.76K | -31.04%473.01K | -22.94%553.21K | -27.68%591.61K | -9.63%739.27K | -31.80%613.72K |
| Current changes in cash | -98.16%-69.86K | 15.86%-67.48K | -40.80%-54.06K | -55.54%-229.68K | -253.43%-75.83K | 51.14%-35.26K | -223.47%-80.2K | 61.66%-38.4K | -87.44%-147.67K | 399.61%49.42K |
| End cash Position | -61.05%170.52K | -49.18%240.39K | -44.35%307.87K | -38.82%361.93K | -38.82%361.93K | -28.67%437.76K | -31.04%473.01K | -22.94%553.21K | -19.97%591.61K | -19.97%591.61K |
| Free cash from | -98.16%-69.86K | 15.86%-67.48K | -40.80%-54.06K | -55.54%-229.68K | -253.43%-75.83K | 51.14%-35.26K | -223.47%-80.2K | 61.66%-38.4K | -87.44%-147.67K | 399.56%49.42K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.